Join Growin Stock Community!

Repligen corporationRGEN.US Overview

US StockHealthcare
(No presentation for RGEN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RGEN AI Insights

RGEN Overall Performance

RGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RGEN Recent Performance

-1.62%

Repligen corporation

0.05%

Avg of Sector

-0.31%

S&P500

RGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RGEN Key Information

RGEN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RGEN Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Price of RGEN

RGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.87
PE Ratio (TTM)
149.69
Forward PE
56.07
PS Ratio (TTM)
9.82
PB Ratio
3.57
Price-to-FCF
76.57
METRIC
VALUE
vs. INDUSTRY
Gross Margin
52.32%
Net Margin
6.62%
Revenue Growth (YoY)
17.59%
Profit Growth (YoY)
44.10%
3-Year Revenue Growth
1.95%
3-Year Profit Growth
2.63%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.87
PE Ratio (TTM)
149.69
Forward PE
56.07
PS Ratio (TTM)
9.82
PB Ratio
3.57
Price-to-FCF
76.57
Gross Margin
52.32%
Net Margin
6.62%
Revenue Growth (YoY)
17.59%
Profit Growth (YoY)
44.10%
3-Year Revenue Growth
1.95%
3-Year Profit Growth
2.63%

  • When is RGEN's latest earnings report released?

    The most recent financial report for Repligen corporation (RGEN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RGEN's short-term business performance and financial health. For the latest updates on RGEN's earnings releases, visit this page regularly.

  • What is the operating profit of RGEN?

    According to the latest financial report, Repligen corporation (RGEN) reported an Operating Profit of 16.35M with an Operating Margin of 8.26% this period, representing a growth of 144.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is RGEN's revenue growth?

    In the latest financial report, Repligen corporation (RGEN) announced revenue of 197.91M, with a Year-Over-Year growth rate of 18.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does RGEN have?

    As of the end of the reporting period, Repligen corporation (RGEN) had total debt of 689.95M, with a debt ratio of 0.23. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RGEN have?

    At the end of the period, Repligen corporation (RGEN) held Total Cash and Cash Equivalents of 566.02M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does RGEN go with three margins increasing?

    In the latest report, Repligen corporation (RGEN) achieved the “three margins increasing” benchmark, with a gross margin of 52.5%%, operating margin of 8.26%%, and net margin of 6.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RGEN's profit trajectory and future growth potential.

  • Is RGEN's EPS continuing to grow?

    According to the past four quarterly reports, Repligen corporation (RGEN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RGEN?

    Repligen corporation (RGEN)'s Free Cash Flow (FCF) for the period is 17.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 36.93% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RGEN?

    The latest valuation data shows Repligen corporation (RGEN) has a Price-To-Earnings (PE) ratio of 153.98 and a Price/Earnings-To-Growth (PEG) ratio of -11.76. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.